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Introduction
Since biologicals antagonize cytokines or receptors
involved in the immune system, one could fear that their
(long-term) use might affect the quality of the immune
system, leading to a defective defense mechanism against
infections and tumors, an insufficient response to vacci-
nations, or a flawed immunoregulation resulting in auto-
immunity or autoinflammation. Finally, a biological agent
itself can be handled as an antigen by the immune sys-
tem, producing antibodies against the biological.
Objectives
To provide a current overview of adverse events for each
biological agent used in JIA calculated as incidence per
100 patientyears for the following categories: serious infec-
tions, tuberculosis, malignancies, response to vaccination,
new-onset autoimmune diseases and development of anti-
drug antibodies.
Methods
This study is an in-depth review resulting from a meta-
analysis of all the available data on pubmed concerning
the (immunological) side effects of biological response
modifiers used to treat juvenile arthritis.
Results
The immunological consequences of the long-term use of
biologicals differ per agent and are highly dependent on
concomitant medication. Infection risk is mainly asso-
ciated with JIA itself and moderate to high doses of ster-
oids and not the use of a biological, although tocilizumab
might be an exception to this rule. Malignancies do not
seem to occur more in JIA patients using anti-TNF ther-
apy, although the background rate of JIA patients might
be higher than that of the general population. Generally,
the immunogenicity of vaccines is good in JIA patients,
but one should be cautious when administering new live
attenuated vaccines in patients with high dose immuno-
suppressants, including biologicals. There is an increased
incidence of demyelinating diseases, IBD and develop-
ment of mostly clinically irrelevant auto-immune antibo-
dies in JIA patients on anti-TNF. The occurrence of
uveitis does not seem to be increased in patients with
etanercept or abatacept. Anti-drug antibody formation is
seen in many patients with monoclonal antibodies, espe-
cially when they do not use concomitant MTX, but these
antibodies are mostly not correlated to clinical events.
Conclusion
There are large differences in side effects between various
agents and there is a clear need for an international and
standardized collection of post-marketing surveillance
data of biologicals in the vulnerable group of JIA patients.
Such an international pharmacovigilance database, called
Pharmachild, has now been started.
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